What do systematic reviews say?

Morning vs evening inhalation of dornase alfa

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low

Morning vs evening inhalation of dornase alfa

Morning showed no clear difference in FEV1 (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low

Morning vs evening inhalation of dornase alfa

Morning showed no clear difference in FVC (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low

Morning vs evening inhalation of dornase alfa

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low

Morning vs evening inhalation of dornase alfa

The review found no eligible studies for this question.

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Morning bright light vs afternoon bright light

Morning bright light showed no clear difference in alertness compared with afternoon bright light (low certainty).

• Workplace lighting for improving alertness and mood in daytime workers 2018 · Cochrane Headline outcomes only
  MD 7
  1 study · 30 participants
  Low

Morning bright light vs afternoon bright light

Morning bright light showed no clear difference in mood compared with afternoon bright light (low certainty).

• Workplace lighting for improving alertness and mood in daytime workers 2018 · Cochrane Headline outcomes only
  RR 1.6 [0.81, 3.2]
  1 study · 30 participants
  Low

Morning bright light vs afternoon bright light

Morning bright light showed no clear difference in adverse events (frequency) compared with afternoon bright light (low certainty).

• Workplace lighting for improving alertness and mood in daytime workers 2018 · Cochrane Headline outcomes only
  RR 0.53 [0.26, 1.07]
  1 study · 30 participants
  Low

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  15 participants
  Very low

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antihistamine‐analgesic‐decongestant vs placebo

Antihistamine‐analgesic‐decongestant may leads to lower global evaluation: on the morning after evening dosing (included… compared with placebo (low certainty).

• Oral antihistamine‐decongestant‐analgesic combinations for the common cold 2022 · Cochrane Headline outcomes only
  OR 0.47 [0.33, 0.67]
  2 studies · 548 participants
  Low

Clarithromycin vs placebo

• Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Insulin glargine vs NPH insulin

Summary of findings: insulin glargine showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.83 [0.62, 1.12]
  6 studies · 1893 participants
  Moderate

Atorvastatin vs placebo

It is very uncertain whether atorvastatin changes lung function: change in morning PEF compared with placebo (very low certainty).

• Statins for asthma 2020 · Cochrane Headline outcomes only
  MD 12.32
  1 study · 60 participants
  Very low

Intervention not reported

• Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 218 participants
  Moderate